Table 3.
Smoking cessation rates at 12 and 26 weeks (n=188).
| Outcome | Overall, n (%) | Pivot, n (%) | QuitGuide, n (%) | Odds ratio (95% CI) | P value | Relative risk (95% CI)a | P value | |
| 12 weeks | ||||||||
|
|
7-day PPAb; ITTc | 59 (31.4) | 33 (35.1) | 26 (27.7) | 1.4 (0.8-2.7) | .28 | 1.2 (0.8-1.8) | .50 |
|
|
7-day PPA; responderd | 59 (32.2) | 33 (35.9) | 26 (28.6) | 1.4 (0.8-2.7) | .30 | 1.2 (0.8-1.8) | .53 |
|
|
30-day PPA; ITT | 48 (25.5) | 27 (28.7) | 21 (22.3) | 1.4 (0.7-2.8) | .32 | 1.2 (0.7-1.9) | .56 |
|
|
30-day PPA; responderd | 48 (26.2) | 27 (29.3) | 21 (23.1) | 1.4 (0.7-2.7) | .35 | 1.2 (0.7-1.9) | .59 |
|
|
Biochemically confirmed abstinence; ITTe | 39 (20.7) | 27 (28.7) | 12 (12.8) | 2.8 (1.3-6.1) | .008 | 2.3 (1.2-4.2) | .008 |
|
|
Biochemically confirmed abstinence; responderd,e | 39 (21.3) | 27 (29.3) | 12 (13.2) | 2.8 (1.3-6.1) | .009 | 2.3 (1.2-4.1) | .009 |
|
|
Self-reported abstinence from all tobacco products; ITT | 56 (29.8) | 31 (33) | 25 (26.6) | 1.2 (0.6-2.3) | .56 | 1.1 (0.7-1.6) | .82 |
|
|
Self-reported abstinence from all tobacco products; responderd | 56 (30.6) | 31 (33.7) | 25 (27.5) | 1.2 (0.6-2.2) | .60 | 1.0 (0.7-1.6) | .87 |
| 26 weeks | ||||||||
|
|
7-day PPA; ITTc | 59 (31.4) | 34 (36.2) | 25 (26.6) | 1.7 (0.9-3.2) | .12 | 1.3 (0.8-1.9)f | .27 |
|
|
7-day PPA; responderg | 59 (32.8) | 34 (37.8) | 25 (27.8) | 1.7 (0.9-3.2) | .13 | 1.5 (1.0-2.3) | .06 |
|
|
30-day PPA; ITT | 51 (27.1) | 30 (31.9) | 21 (22.3) | 1.7 (0.9-3.4) | .12 | 1.4 (0.9-2.2) | .18 |
|
|
30-day PPA; responderg | 51 (28.3) | 30 (33.3) | 21 (23.3) | 1.7 (0.9-3.4) | .13 | 1.4 (0.9-2.22) | .19 |
|
|
Biochemically confirmed abstinence; ITTh | 40 (21.3) | 26 (27.7) | 14 (14.9) | 2.3 (1.1-4.8) | .03 | 1.9 (1.1-3.5) | .02 |
|
|
Biochemically confirmed abstinence; responderg,h | 40 (22.2) | 26 (28.9) | 14 (15.6) | 2.3 (1.1-4.8) | .03 | 1.9 (1.1-3.4) | .02 |
|
|
Self-reported continuous abstinence; ITT | 39 (20.7) | 24 (25.5) | 15 (16.0) | 1.9 (0.9-3.8) | .10 | 1.6 (0.9-2.8) | .11 |
|
|
Self-reported continuous abstinence; responderi | 39 (21.8) | 24 (26.7) | 15 (16.9) | 1.8 (0.9-3.9) | .11 | 1.6 (0.9-2.8) | .12 |
|
|
Biochemically confirmed continuous abstinence; ITT | 29 (15.4) | 20 (21.3) | 9 (9.6) | 2.7 (1.1-6.4) | .03 | 2.2 (1.1-4.6)f | .03 |
|
|
Biochemically confirmed continuous abstinence; responderi | 29 (16.2) | 20 (22.2) | 9 (10.1) | 2.7 (1.1-6.3) | .03 | 2.3 (1.1-4.7) | .02 |
|
|
Self-reported abstinence from all tobacco products; ITT | 55 (29.3) | 32 (34) | 23 (24.5) | 1.6 (0.9-3.1) | .13 | 1.5 (1.0-2.3) | .06 |
|
|
Self-reported abstinence from all tobacco products; responderg | 55 (30.6) | 32 (35.6) | 23 (25.6) | 1.6 (0.8-3.1) | .16 | 1.5 (1.0-2.2) | .08 |
aNegative binomial regression.
bPPA: point prevalence abstinence.
cITT: intention to treat; total N=188: 94 in Pivot and 94 in QuitGuide.
dResponders to 12-week questionnaire; N=183 total: 92 in Pivot and 91 in QuitGuide.
eCompleters of 12-week biovalidation visit; n=50 total: 29 in Pivot and 21 in QuitGuide.
fLog-link Poisson regression.
gResponders to 26-week questionnaire; N=180 total: 90 in Pivot and 90 in QuitGuide (includes responses from 1 partial responder).
hCompleters of 26-week biovalidation visit; n=50 total: 29 in Pivot and 21 in QuitGuide.
iResponders to 26-week questionnaire; N=179 total: 90 in Pivot and 89 in QuitGuide.